AOR:LSE-Rua Life Sciences Plc (GBX)

COMMON STOCK | Biotechnology | LSE

Last Closing Price

GBX 126.50

Change

0.00 (0.00)%

Market Cap

GBX 0.02B

Volume

0.06M

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Rua Life Sciences Plc, together with its subsidiaries, provides polymers, services, and products to the medical device industry in the United Kingdom. The company operates as a contract developer and manufacturer of medical devices; and licensor of Elast-Eon and ECSil implantable co-polymers used in cardiology and urological applications, including pacing leads, cardiac cannulae, and stent devices, as well as Reaction Injection Molding technology for use in high-precision medical device components. It also develops bore polymer sealed grafts and soft tissue patches; and tri leaflet polymeric heart valves. The company was formerly known as AorTech International plc and changed its name to Rua Life Sciences Plc in June 2020. Rua Life Sciences Plc was incorporated in 1996 and is based in Glasgow, the United Kingdom. Address: 163 Bath Street, Glasgow, United Kingdom, G2 4SQ

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
HCM:LSE Hutchison China MediTech Limit..

-32.00 (-6.25%)

GBX3.41B 17.41 N/A
ABC:LSE Abcam plc

+41.00 (+3.50%)

GBX2.62B 198.17 63.68
GNS:LSE Genus plc

-28.00 (-0.72%)

GBX2.51B 61.78 27.80
PRTC:LSE PureTech Health plc

+1.00 (+0.39%)

GBX0.73B 2.21 0.90
OXB:LSE Oxford Biomedica plc

-22.00 (-2.62%)

GBX0.67B N/A 615.00
AVCT:LSE Avacta Group Plc

+3.00 (+1.95%)

GBX0.39B N/A N/A
ERGO:LSE Ergomed plc

+2.00 (+0.25%)

GBX0.38B 60.00 36.25
SLN:LSE Silence Therapeutics plc

+12.00 (+2.75%)

GBX0.37B N/A N/A
VRP:LSE Verona Pharma plc

-5.00 (-7.14%)

GBX0.27B N/A N/A
SNG:LSE Synairgen plc

-8.00 (-4.62%)

GBX0.25B N/A N/A

ETFs Containing AOR

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 25.25% 45% F 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.25% 45% F 89% B+
Trailing 12 Months  
Capital Gain 166.32% 74% C 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 166.32% 74% C 95% A
Trailing 5 Years  
Capital Gain 241.89% 91% A- 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 241.89% 91% A- 93% A
Average Annual (5 Year Horizon)  
Capital Gain 73.19% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 73.19% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 133.74% N/A N/A N/A N/A
Risk Adjusted Return 54.73% N/A N/A N/A N/A
Market Capitalization 0.02B 21% F 23% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 9.43 38% F 7% F
Price / Cash Flow Ratio -46.75 85% B 93% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -17.53% 73% C 24% F
Return on Invested Capital -35.68% 53% F 8% F
Return on Assets -12.71% 64% D 13% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.28 38% F 17% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector